Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
tumor associated antigen specific cytotoxic t lymphocytes (1 trial)
Rhabdomyosarcoma (Phase 1)
Trials (1 total)
Trial APIs (1 total)